We've found
8,262 Colorectal Cancer
clinical trials
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Clinical Trial
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Clinical Trial
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Neurology, Oncology Clinical Trial
Lidocaine for Oxaliplatin-induced Neuropathy
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Longitudinal Performance of Epi proColon
Status: Enrolling
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Longitudinal Performance of Epi proColon
Status: Enrolling
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
8,262 Colorectal Cancer
clinical trials
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Clinical Trial
Updated: 12/31/1969
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Clinical Trial
Updated: 12/31/1969
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
Updated: 12/31/1969
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Lidocaine for Oxaliplatin-induced Neuropathy
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/13/2018
Longitudinal Performance of Epi proColon
Status: Enrolling
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/13/2018
Longitudinal Performance of Epi proColon
Status: Enrolling
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Updated: 12/31/1969
Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Updated: 12/31/1969
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Updated: 12/31/1969
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Updated: 12/31/1969
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Updated: 12/31/1969
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Metastatic Clinical Trial
Updated: 12/31/1969
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials